Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;87(5):497-503.
doi: 10.1080/17453674.2016.1205168. Epub 2016 Jun 30.

Arthroplasty for tenosynovial giant cell tumors

Floortje G M Verspoor  1 , Gerjon Hannink  1 , Anouk Scholte  1 , Ingrid C M Van Der Geest  1 , H W Bart Schreuder  1
Affiliations

Arthroplasty for tenosynovial giant cell tumors

Floortje G M Verspoor et al. Acta Orthop. 2016 Oct.

Abstract

Background and purpose - Tenosynovial giant cell tumors (t-GCTs) can behave aggressively locally and affect joint function and quality of life. The role of arthroplasty in the treatment of t-GCT is uncertain. We report the results of arthroplasty in t-GCT patients. Patients and methods - t-GCT patients (12 knee, 5 hip) received an arthroplasty between 1985 and 2015. Indication for arthroplasty, recurrences, complications, quality of life, and functional scores were evaluated after a mean follow-up time of 5.5 (0.2-15) years. Results - 2 patients had recurrent disease. 2 other patients had implant loosening. Functional scores showed poor results in almost half of the knee patients. 4 of the hip patients scored excellent and 1 scored fair. Quality of life was reduced in 1 or more subscales for 2 hip patients and for 5 knee patients. Interpretation - In t-GCT patients with extensive disease or osteoarthritis, joint arthroplasty is an additional treatment option. However, recurrences, implant loosening, and other complications do occur, even after several years.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Gradient-echo-based MRI image from a patient with recurrent t-GCT (right knee). There was very low signal intensity corresponding to hemosiderin depositions anterior to the lateral meniscus, extending to the infrapatellar fat pad. Furthermore, there was a hemosiderin deposition in the recessus lateralis posterior to the lateral femoral condyle. These localizations corresponded to recurrent Dt-GCT, which was confirmed by surgical removal.
Figure 2.
Figure 2.
Gradient-echo-based MRI image from a patient with recurrent t-GCT (left knee). There was very low signal intensity corresponding to hemosiderin depositions, particularly in the posterior compartment of the joint and in the popliteal fossa. There was also osseous destruction.
See this image and copyright information in PMC

References

    1. Bunting D, Kampa R, Pattison R. An unusual case of pigmented villonodular synovitis after total knee arthroplasty. J Arthroplasty 2007; 22 (8): 1229–31. - PubMed
    1. Chiari C, Pirich C, Brannath W, Kotz R, Trieb K. What affects the recurrence and clinical outcome of pigmented villonodular synovitis? Clin Orthop Relat Res 2006; 450: 172–8. - PubMed
    1. de Kam D C, Busch V J, Veth R P, Schreurs B W. Total hip arthroplasties in young patients under 50 years: limited evidence for current trends. A descriptive literature review. Hip Int 2011; 21 (5): 518–25. - PubMed
    1. de saint Aubain Somerhausen N, van de Rijn M. Tenosynovial giant cell tumour, diffuse/localized type In: Fletcher C D, Bridge J A, Hogedoorn P C, Mertens F, eds. WHO classification of tumours of Soft Tissue and Bone 2013; 5 (4th ed. Lyon: IARC Press; ).
    1. Della Valle A G, Piccaluga F, Potter H G, Salvati E A, Pusso R. Pigmented villonodular synovitis of the hip: 2- to 23-year followup study. Clin Orthop Relat Res 2001; (388): 187–99. - PubMed

MeSH terms

LinkOut - more resources